Bruush Oral Care (BRSHF) 20-F 10 Mar 23 2022 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Oct. 31, 2022 shares
Entity Addresses [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Oct. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	001-41460
Entity Registrant Name	BRUUSH ORAL CARE INC.
Entity Central Index Key	0001913210
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	128 West Hastings Street
Entity Address, Address Line Two	Unit 210
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6B 1G8
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	8,150,875
Auditor Firm ID	1173
Auditor Name	DALE MATHESON CARR-HILTON LABONTE LLP
Auditor Location	Vancouver, Canada
Common shares without parvalue [member]
Entity Addresses [Line Items]
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	BRSH
Security Exchange Name	NASDAQ
Warrants to purchase common shares [member]
Entity Addresses [Line Items]
Title of 12(b) Security	Warrants to purchase Common Shares
Trading Symbol	BRSHW
Security Exchange Name	NASDAQ
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	128 West Hastings Street
Entity Address, Address Line Two	Unit 210
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V6B 1G8
City Area Code	(844)
Local Phone Number	427-8774
Contact Personnel Name	Aneil Manhas
Contact Personnel Email Address	aneil@bruush.com

Statements of Financial Positio

Statements of Financial Position - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Current
Cash	$ 72,921	$ 14,530	$ 692,647
Term deposit	18,506
Accounts and other receivables	175,256	161,047	81,159
Inventory	241,341	774,117	1,176,247
Prepaid expenses and deposits	677,474	81,574	118,369
Total current assets	1,185,498	1,031,268	2,068,422
Non-current
Intangible asset		11,466
Property and equipment	5,619	7,432	3,196
Total assets	1,191,117	1,050,166	2,071,618
Current
Accounts payable and accrued liabilities	1,345,288	3,366,062	308,719
Loan payable		27,144	17,580
Deferred revenue	6,045	17,181	92,121
Warrant derivative	1,242,580	1,582,977	1,490,059
Total liabilities	2,593,913	4,993,364	1,908,479
SHAREHOLDERS’ EQUITY
Share capital	23,845,704	13,276,909	13,264,251
Reserves	1,137,814	400,936	308,660
Accumulated deficit	(26,386,314)	(17,621,043)	(13,409,772)
Total shareholders’ equity	(1,402,796)	(3,943,198)	163,139
Total liabilities and shareholders’ deficiency	$ 1,191,117	$ 1,050,166	$ 2,071,618

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Profit or loss [abstract]
Revenues	$ 1,965,441	$ 2,632,442	$ 901,162
Cost of goods sold	978,243	822,383	291,195
Gross Profit	987,198	1,810,059	609,967
Expenses
Advertising and marketing	2,806,260	7,162,046	2,670,447
Amortization and depreciation expense	5,498	15,348
Commission	26,339	91,050	11,207
Consulting	868,442	1,197,831	556,864
Interest and bank charges	60,183	1,155,288	18,130
Inventory management		47,405
Merchant fees	68,073	99,293	39,180
Office and administrative expenses	93,900	328,956	75,194
Professional fees	241,854	521,064	222,870
Research and development		96,431
Salaries and wages	282,003	1,222,171	93,460
Share-based compensation	92,276	279,622	4,949,441
Shipping and delivery	511,566	832,395	304,591
Travel and entertainment	100,068	259,372	29,225
Total expenses	(5,156,462)	(13,308,272)	(8,970,609)
Other items
Government grant	8,763		14,139
Foreign exchange	42,148	(153,076)	(7,719)
Gain (loss) on revaluation of warrant derivative	(92,918)	5,740,202	(536,209)
Financing costs		(2,688,034)
Other loss		(166,150)
Total other items	(42,007)	2,732,942	(529,789)
Net and comprehensive loss	$ (4,211,271)	$ (8,765,271)	$ (8,890,431)
Loss per share - Basic and diluted	$ (1.07)	$ (1.83)	$ (8.43)
Weighted average number of common shares outstanding - basic and diluted	3,929,520	4,800,972	1,054,371

Statement of Changes in Shareho

Statement of Changes in Shareholders' Equity - USD ($)	Issued capital [member]	Subscriptions received [member]	Other reserves [member]	Retained earnings [member]	Total
Beginning balance, value at Jan. 31, 2020	$ 4,302,411	$ 301,886		$ (4,519,341)	$ 84,956
Beginning balance, shares at Jan. 31, 2020	1,245,683
IfrsStatementLineItems [Line Items]
Private placement of shares - $5.56	$ 988,000	(301,886)			686,114
Private placement of shares - $5.56, shares	239,015
Shares issued for services	$ 4,525,206				4,525,206
Shares issued for services, shares	1,105,955
Private placement units - $2.32	$ 746,365				746,365
Private placement units - $2.32, shares	535,491
Private placement units - $6.95	$ 3,265,078				3,265,078
Private placement units - $6.95, shares	756,230
Share issuance cost - shares	$ (38,745)		38,745
Share issuance cost - shares	46,485
Share issuance cost – broker warrants	$ (123,981)		123,981
Share issuance cost - cash	(400,083)				(400,083)
Stock options granted			145,934		145,934
Net and comprehensive loss				(8,890,431)	(8,890,431)
Ending balance, value at Jan. 31, 2021	$ 13,264,251		308,660	(13,409,772)	163,139
Ending balance, shares at Jan. 31, 2021	3,928,860
IfrsStatementLineItems [Line Items]
Shares issued for services	$ 12,658				12,658
Shares issued for services, shares	2,277
Net and comprehensive loss				(4,211,271)	(4,211,271)
Share-based compensation			92,276		92,276
Ending balance, value at Oct. 31, 2021	$ 13,276,909		400,936	(17,621,043)	(3,943,198)
Ending balance, shares at Oct. 31, 2021	3,931,137
IfrsStatementLineItems [Line Items]
Shares issued for services	$ 140,310				140,310
Shares issued for services, shares	50,000
Net and comprehensive loss				(8,765,271)	(8,765,271)
Share-based compensation			279,622		279,622
Share cancellation
Share cancellation, shares	(316,023)
IPO	$ 10,463,042				10,463,042
IPO, shares	3,728,549
IPO costs - cash	$ (1,840,861)				(1,840,861)
IPO costs – broker warrants	(318,581)		321,209		2,628
Financing costs	$ 2,124,885				2,124,885
Financing costs, shares	757,212
Derecognition of warrant derivative			136,047		136,047
Ending balance, value at Oct. 31, 2022	$ 23,845,704		$ 1,137,814	$ (26,386,314)	$ (1,402,796)
Ending balance, shares at Oct. 31, 2022	8,150,875

Statement of Changes in Share_2

Statement of Changes in Shareholders' Equity (Parenthetical)	12 Months Ended
	Jan. 31, 2021 $ / shares
Private placement [member]
IfrsStatementLineItems [Line Items]
Share price	$ 5.56
Private placement one [member]
IfrsStatementLineItems [Line Items]
Share price	2.32
Private placements two [member]
IfrsStatementLineItems [Line Items]
Share price	$ 6.95

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Cash flows from operating activities
Net loss	$ (4,211,271)	$ (8,765,271)	$ (8,890,431)
Items not affecting cash:
Amortization and depreciation	5,498	15,348
Government grant	(8,763)		(14,139)
Share-based compensation	92,276	279,622	4,949,441
Consulting	12,658	140,310
Loss (gain) on revaluation of warrant derivative	92,918	(5,740,202)	536,209
Interest expense	2,699	995,901	1,782
Unrealized foreign exchange	1,376	(1,771)	1,431
Financing costs		2,613,034
Accounts and other receivables	(79,888)	(14,209)	(68,190)
Inventory	402,130	589,037	(577,656)
Term deposit		(18,506)
Prepaid expenses and deposits	36,795	(652,161)	(114,917)
Accounts payable and accrued liabilities	3,057,343	(2,020,774)	31,999
Deferred revenue	(74,940)	(11,136)	92,121
Net cash flows used in operating activities	(671,169)	(12,590,778)	(4,052,350)
Cash flows from investing activities
Purchase of property and equipment	(6,201)	(2,042)	(3,196)
Purchase of intangible asset	(15,000)
Net cash flows used in investing activities	(21,201)	(2,042)	(3,196)
Cash flows from financing activities
Proceeds from promissory notes net of costs		3,860,750
Repayment of promissory notes		(4,852,867)
Proceeds from equity financings		15,510,764	4,973,023
Share issuance costs		(1,840,861)
Broker warrants		2,628
Repayment of loans		(29,203)	(433,987)
Proceeds from loans	14,253		28,506
Net cash flows provided by financing activities	14,253	12,651,211	4,567,542
Change in cash	(678,117)	58,391	511,996
Cash
Beginning of year	692,647	14,530	180,651
End of year	14,530	72,921	692,647
Supplemental cash flow disclosure
Interest		311,617
Taxes paid

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Nature Of Operations And Going Concern
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN Bruush Oral Care Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on October 10, 2017. The Company is in the business of selling electric toothbrushes. The Company is located at 128 West Hastings Street, Unit 210, Vancouver, British Columbia V6B 1G8. The Company’s common shares are listed for trading on NASDAQ under the symbol “BRSH”. As of October 31, 2022, the Company had a working capital deficit of $ 1,408,415 26,386,314 These factors form a material uncertainty that may cast significant doubt upon the Company’s ability to continue as a going concern. These financial statements do not give effect to adjustments to the carrying value and classification of assets and liabilities and related expense that would be necessary should the Company be unable to continue as a going concern. If the going concern assumption is not appropriate, material adjustments to the statements could be required.
Working capital deficit	$ 1,408,415
Accumulated deficit	$ 26,386,314	$ 17,621,043	$ 13,409,772

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Oct. 31, 2022
Basis Of Presentation
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Statement of compliance These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Issues Committee (“IFRIC”). The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all periods presented, unless otherwise stated. The Company has changed its fiscal year end from January 31 to October 31, which became effective for the period ended October 31, 2021. The Company determined that the change in year end would better reflect the annual business cycle given that the holiday season (November and December) is a peak period for sales. Given the fiscal year ended October 31, 2021 is for a 9-month period, the results may not be comparable to the 12-month period ended October 31, 2022. These financial statements were approved by the Board of Directors on March 10, 2023. Basis of presentation These financial statements have been prepared on a historical cost basis and presented in U.S. dollars which is the functional currency of the Company. The financial statements of the Company have been prepared on an accrual basis, except for cash flow information. The financial statements have been prepared on a historical cost basis except for warrants and options, which are measured at fair value. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS		3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS Revenue recognition The Company’s revenue is generated from the sale of finished product to customers. Those sales predominantly contain a single performance obligation and revenue is recognized at a single point in time when ownership, risks and rewards transfer, which is typically the date of receipt by the customer. When the Company has collected payment from a customer, but the product is in transit, the Company will defer the recognition of the product sale in revenues until such time the product is delivered to the customer. A provision for payment discounts and product return allowances is recorded as a reduction of sales in the same period the revenue is recognized. The revenue recorded is presented net of sales and other taxes the Company collect on behalf of governmental authorities. Foreign currency translation The functional currency of each entity is determined using the currency of the primary economic environment in which that entity operates. The Company’s financial statements are presented in U.S. dollars. The functional currency for the Company is the U.S. dollar. Foreign currency transactions are translated into the functional currency of the Company, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the remeasurement of monetary items denominated in foreign currency at year end exchange rates are recognized in the statement of loss and comprehensive loss. Non-monetary items are not retranslated at year end and are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value which are translated using the exchange rates at the date when fair value was determined. Inventory Inventory consists entirely of finished goods and is valued at the lower of cost or net realizable value. The cost of inventory is maintained using the average-cost method. The net realizable value of finished goods is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods inventory is based on landed cost, which includes all costs incurred to bring inventory to the Company’s distribution centers including product costs, inbound freight and duty. If the Company determines that the estimated net realizable value of its inventory is less than the carrying value of such inventory, it records a charge to cost of goods sold. Property and equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred; cost of major additions and betterments are capitalized. Upon sale or other disposition of a depreciable asset, cost and accumulated depreciation are removed from property and equipment and any gain or loss is reflected as a gain or loss from operations. The estimated useful life of the computers and software is 3 years BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Intangible assets Purchased intangible assets are recognized as assets in accordance with IAS 38 – Intangible Assets, where it is probable that the use of the asset will generate future economic benefits and where the cost of the asset can be determined reliably. Intangible assets acquired are initially recognized at cost of purchase and are subsequently carried at cost less accumulated amortization, if applicable, and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. All finite-lived intangible assets are stated at cost less accumulated impairment. Impairment of assets The Company performs impairment tests on its long-lived assets, including property and equipment and intangible assets, when new events or circumstances occur, or when new information becomes available relating to their recoverability. When the recoverable amount of each separately identifiable asset or cash generating unit (“CGU”) is less than its carrying value, the asset or CGU’s assets are written down to their recoverable amount with the impairment loss charged against profit or loss. A reversal of the impairment loss in a subsequent period will be charged against profit or loss if there is a significant reversal of the circumstances that caused the original impairment. The impairment will be reversed up to the amount of depreciated carrying value that would have otherwise occurred if the impairment loss had not occurred. Leases The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. Lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments or a change in the assessment of an option to purchase the underlying asset. The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. As at October 31, 2022, October 31, 2021 and January 31, 2021, the Company did not have any leases in place. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Research and development costs Expenditure on research activities, undertaken with the prospect of gaining new technical knowledge and understanding, is recognized in profit or loss as incurred. During the year ended October 31, 2022, $ 96,431 (Nine months ended October 31, 2021 - $ Nil Nil of research and development costs were recorded in the Statement of Comprehensive Loss. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred. Research and development costs incurred subsequent to the acquisition of externally acquired intangible assets and on internally generated intangible assets are accounted for as research and development costs. As at October 31, 2022, October 31, 2021 and January 31, 2021, the Company has not capitalized any research and development costs. Financial instruments (a) Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. (b) Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of loss and comprehensive loss in the period in which they arise. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Debt investments at FVTOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVTOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. (c) Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. (d) Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. Income taxes Current income tax: Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred tax: Deferred tax is recognized on temporary differences at the reporting date arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that future taxable income will be available to allow all or part of the temporary differences to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted and are expected to apply by the end of the reporting period. Deferred tax assets and deferred income tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority. Loss per share Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. For all periods presented, the loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Share capital Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares are recognized as a deduction from shareholders’ equity, net of tax. In the event that the financing is not completed, these costs are expensed to profit or loss. The Company may engage in equity financing transactions to obtain the funds necessary to continue operations. These equity financing transactions may involve issuance of common shares or units. A unit comprises a certain number of common shares and a certain number of share purchase warrants. Depending on the terms and conditions of each financing agreement, the warrants are exercisable into additional common shares prior to expiry at a price stipulated by the agreement. Warrants that are part of units are assigned a residual value if the unit is issued at a price exceeding the market price of underlying share at the time of issuance otherwise the warrants are assigned no value and included in share capital with the common shares that are concurrently issued. Warrants that are issued as payment for an agency fee or other transactions costs are accounted for as share-based payment transaction costs. Warrants that are exercisable in currencies other than the Company’s functional currency of U.S. dollars are considered to be derivative financial instruments. The Company presents such warrants as derivative liabilities on the balance sheet and measures them at fair value at the end of each reporting period. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Critical accounting estimates and significant management judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Fair value measurement of broker warrants and warrant derivative The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date on which they are granted. When the fair value of financial assets and financial liabilities recorded in the Statements of Financial Position cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques. Estimating fair value for broker warrants and the warrant derivative requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires the determination of the most appropriate inputs to the valuation model including the expected remaining life of the broker warrants and the warrant derivative, fair value of the underlying stock, volatility, risk-free interest rate and dividend yield and making assumptions about them. Where possible the Company will utilize contractual and publicly available information to determine valuation model inputs. If no such information is available, the Company will use historical performance and if required, the Company will make estimations based on the best information available. Expected remaining life is determined using the information in the warrant terms, fair value of the underlying stock is determined based the most recently completed financing, volatility is estimated based on market data and industry assessment, risk-free interest rate is determined based on central bank rates for a similar period to the expected remaining life and dividend yield is estimated using the Company’s past performance and future expectations. The assumptions and models used for estimating fair value for broker warrants and the warrant derivative are disclosed in Note 12. These are either classified as equity instruments or derivative liabilities subject to whether the exercise price is fixed or variable. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Income taxes The Company recognizes the tax benefit from an uncertain tax position only if it is probable that the tax position will be sustained based on its technical merits. The Company measures and record the tax benefits from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s estimated liabilities related to these matters are adjusted in the period in which the uncertain tax position is effectively settled, the statute of limitations for examination expires or when additional information becomes available. The amount and timing of future taxable income for unrecognized tax benefits requires the use of assumptions and significant judgement to estimate the exposures associated with our various filing positions. The Company has not recognized the value of any deferred tax assets in its statements of financial position. Although the Company believes that the judgements and estimates made are reasonable, actual results could differ and resulting adjustments could materially affect our effective income tax rate and income tax provision. Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: - The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; - The determination of the Company’s functional currency; and - Whether there are indicators of impairment of the Company’s long-lived assets.
Research and development expense		$ 96,431
Computer equipment [member]
IfrsStatementLineItems [Line Items]
Property, plant and equipment estimated useful life		P3Y

TERM DEPOSIT

TERM DEPOSIT	9 Months Ended	12 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2022 CAD ($)
Term Deposit
TERM DEPOSIT		4. TERM DEPOSIT The Company holds a non-redeemable CAD$ 25,000 18,316 4.56 August 9, 2023 190 Nil
Non-redeemable term deposit		$ 18,316	$ 25,000
Accrues interest of term deposit		4.56%
Maturity date of term deposit		Aug. 09, 2023
Interest income		$ 190

ACCOUNTS AND OTHER RECEIVABLES

ACCOUNTS AND OTHER RECEIVABLES	12 Months Ended
	Oct. 31, 2022
Accounts And Other Receivables
ACCOUNTS AND OTHER RECEIVABLES	5. ACCOUNTS AND OTHER RECEIVABLES SUMMARY OF ACCOUNTS AND OTHER RECEIVABLES October 31, 2022 October 31, 2021 January 31, 2021 Trade receivables $ 103,471 $ 36,734 $ 7,206 Sales taxes receivable 71,785 124,313 73,953 Total $ 175,256 $ 161,047 $ 81,159

INVENTORY

INVENTORY - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Disclosure Of Inventory Abstract
INVENTORY		6. INVENTORY Inventory consisted entirely of finished goods. During the year ended October 31, 2022, $ 822,383 (9 months ended October 31, 2021 - $ 978,243 12 months ended January 31, 2021 - $ 291,195 ) of inventory was sold and recognized in cost of goods sold, and $ 56,989 (9 months ended October 31, 2021 - $ 35,683 , 12 months ended January 31, 2021 - $ 64,161 ) of inventory was used for promotional purposes and recognized in other expense categories, such as selling and marketing and investor relations. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021
Finished goods	$ 978,243	$ 822,383	$ 291,195
Cost of inventories	$ 35,683	$ 56,989	$ 64,161

PREPAID EXPENSES AND DEPOSITS

PREPAID EXPENSES AND DEPOSITS	12 Months Ended
	Oct. 31, 2022
Prepaid Expenses And Deposits
PREPAID EXPENSES AND DEPOSITS	7. PREPAID EXPENSES AND DEPOSITS SUMMARY OF PREPAID EXPENSES AND DEPOSITS October 31, 2022 October 31, 2021 January 31, 2021 Prepaid expenses $ 191,322 $ 18,246 $ 7,067 Deposits on inventory 475,458 56,261 111,302 Deposits 10,694 7,067 - Total $ 677,474 $ 81,574 $ 118,369

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Oct. 31, 2022
Accounts Payable And Accrued Liabilities
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SUMMARY OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES October 31, 2022 October 31, 2022 January 31, 2021 Accounts payable $ 909,438 $ 2,299,177 $ 236,806 Accrued liabilities 435,850 1,066,885 71,913 Total $ 1,345,288 $ 3,366,062 $ 308,719

LOANS PAYABLE

LOANS PAYABLE					9 Months Ended	12 Months Ended
	Sep. 27, 2022 USD ($)	Sep. 27, 2022 CAD ($)	Apr. 07, 2021 USD ($)	May 05, 2020 USD ($)	Oct. 31, 2021 USD ($)	Oct. 31, 2022 USD ($)	Jan. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Apr. 07, 2021 CAD ($)	May 05, 2020 CAD ($)
IfrsStatementLineItems [Line Items]
LOANS PAYABLE						9. LOANS PAYABLE On May 5, 2020, the Company received a loan in the principal amount of CAD$ 40,000 ($ 28,506 ) under the Canada Emergency Business Account (“CEBA”) program. The loan is non-interest bearing and eligible for CAD$ 10,000 7,127 At issuance, the Company intended to repay the loan by December 31, 2022 and management assessed that the Company will have the financial ability to do so. As it was probable that the conditions for the forgiveness of the loan will be met, the Company has recognized the CAD$ 10,000 ($ 7,127 ) loan forgiveness as government grant income at loan issuance. As the loan was issued at below market rates, the initial fair value of the loan was determined to be $ 20,160 , which was determined using an estimated effective interest rate of 15 %. The difference between the face value of the loan and the fair value of the loans of $ 14,139 has been recognized as government grant income during the year ended January 31, 2021. On September 27, 2022, the Company repaid CAD$ 30,000 ($ 21,902 ) of the loan, and as repayment occurred prior to December 31, 2022, CAD$ 10,000 was forgiven. On April 7, 2021, the Company received an additional CAD$ 20,000 14,253 The additional loan is non-interest bearing and eligible for CAD$ 10,000 7,704 10,000 7,704 7,703 15 8,763 10,000 7,301 10,000 For the year ended October 31, 2022, the Company recognized interest expense of $ 4,838 related to the loans (9 months ended October 31, 2021 - $ 3,315 , 12 months ended January 31, 2021 - $ 1,782 ). As at October 31, 2022, the carrying value of the loans was $ nil 27,144 17,580 BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021
Borrowings					$ 27,144		$ 17,580
Interest expense on borrowings					3,315	$ 4,838	1,782
Canada emergency business account [member]
IfrsStatementLineItems [Line Items]
Borrowings			$ 14,253	$ 28,506						$ 20,000	$ 40,000
Description of loans repayment			The additional loan is non-interest bearing and eligible for CAD$10,000 ($7,704) forgiveness if repaid by December 31, 2022. If not repaid by December 31, 2022, the loan bears interest at 5% per annum and is due on December 31, 2025.	The loan is non-interest bearing and eligible for CAD$10,000 ($7,127) forgiveness if repaid by December 31, 2022. If not repaid by December 31, 2022, the loan bears interest at 5% per annum and is due on December 31, 2025.
Amount of loans forgiveness			$ 7,704					$ 7,127	$ 10,000	10,000
Government grants			7,704	$ 7,127	$ 8,763		$ 14,139			$ 10,000	$ 10,000
Initial fair value of loan			$ 7,703	$ 20,160
Interest rate			15%	15%						15%	15%
Repayments of loans	$ 21,902	$ 30,000
Additional borrowing [member]
IfrsStatementLineItems [Line Items]
Amount of loans forgiveness									$ 10,000
Repayments of loans	$ 7,301	$ 10,000

SENIOR SECURED PROMISSORY NOTES

SENIOR SECURED PROMISSORY NOTES							9 Months Ended	12 Months Ended
	Dec. 03, 2022 USD ($)	Dec. 02, 2022 USD ($)	Sep. 29, 2022 USD ($)	Aug. 04, 2022 USD ($) shares	Apr. 28, 2022 USD ($)	Dec. 03, 2021 USD ($)	Oct. 31, 2021 USD ($)	Oct. 31, 2022 USD ($) Segment	Jan. 31, 2021 USD ($)
IfrsStatementLineItems [Line Items]
SENIOR SECURED PROMISSORY NOTES								10. SENIOR SECURED PROMISSORY NOTES December Financing On December 3, 2021, the Company issued senior secured promissory notes (the “December Senior Secured Promissory Notes”) in the amount of $ 3,000,000 8 Should the Company complete any public offering of securities or any other financing or capital-raising transaction of any kind (each a “Subsequent Offering”) for gross proceeds of over $ 5,000,000 In conjunction with the issuance of the December Senior Secured Promissory Notes, the Company incurred transaction costs consisting of finders’ fees and professional fees in the amount of $ 396,500 22 As part of the agreement, the Company is also to issue units to the holders of the December Senior Secured Promissory Notes (“the Units”) with the same terms as units to be issued as part of the Company’s initial public offering (“IPO”). The number of Units is determined by dividing 50 % of the principal amount of the Secured Promissory Notes by the unit price of the Company’s IPO. Each Unit will comprise of one of the common shares and one warrant (the “Warrants”). Each Warrant is exercisable into one common share at an exercise price equal to the share price of the Company’s IPO. The Warrants will expire five and a half years after the closing of the Company’s IPO. On August 4, 2022, the Company completed its IPO and repaid principal amounts of $ 3,000,000 and $ 130,882 in interest for the December Senior Secured Promissory Notes. In addition to the repayment, the Company issued 360,577 Units to the holders of the December Senior Secured Promissory Notes. The fair value of the Units issued of $ 1,500,000 has been recognized as financing costs during the year ended October 31, 2022. $ 488,149 of the fair value was allocated to the warrants and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: expected dividend yield - 0 %, expected volatility - 66 %, risk-free interest rate – 2.79 % and an expected remaining life - 5 years. April Financing On April 28, 2022, the Company issued senior secured promissory notes (the “April Senior Secured Promissory Notes”) in the amount of $ 1,650,000 December 2, 2022 8 15 The April Senior Promissory Notes were issued with a 10 1,500,000 242,750 55 Should the Company complete any public offering of securities or any Subsequent Offering for gross proceeds of over $ 5,000,000 As part of the agreement, the Company is also to issue shares to the holders of the April Senior Secured Promissory Notes (“the Commitment Shares”) with the same terms as units to be issued as part of the Company’s IPO. The number of Commitment Shares is determined by dividing 100 % of the principal amount of the April Secured Promissory Notes by the share price of the Company’s IPO. On August 4, 2022, the Company completed its IPO and repaid principal amounts of $ 1,650,000 , and $ 71,985 in interest for the April Senior Secured Promissory Notes. In addition to the repayment, the Company issued 396,635 Commitment Shares to the holders of the April Senior Secured Promissory Notes. The fair value of the Commitment Shares issued of $ 1,113,036 has been recognized as financing costs during the year ended October 31, 2022. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 10. SENIOR SECURED PROMISSORY NOTES (continued) On September 29, 2022, the Company paid one of the lenders an additional forebearance fee of $ 75,000 A continuity of the senior secured promissory notes below: SCHEDULE OF SENIOR SECURED PROMISSORY NOTES December Senior Secured Promissory Notes April Senior Secured Promissory Notes Total Balance, January 31, 2021 and October 31, 2021 $ - $ - $ - Additions 3,000,000 1,650,000 4,650,000 Discount - (150,000 ) (150,000 ) Transaction costs (396,500 ) (242,750 ) (639,250 ) Accretion 527,382 464,735 992,117 Repayment (3,130,882 ) (1,721,985 ) (4,852,867 ) Balance, October 31, 2022 $ - $ - $ -
Proceeds from borrowings, classified as financing activities							$ 14,253		$ 28,506
Professtional fee							241,854	521,064	222,870
Repayments of borrowings, classified as financing activities								29,203	433,987
Interest paid, classified as financing activities								$ 311,617
Expected dividend as percentage, share options granted								0%	0%
Expected volatility, share options granted								100%	100%
Risk free interest rate, share options granted								1.11%	0.25%
Issuance of debt							$ 27,144		$ 17,580
December senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Long term debt						$ 3,000,000
Debt interest rate						8%
Professtional fee						$ 396,500
Effective interest rate						22%
Repayments of borrowings, classified as financing activities				$ 3,000,000
Interest paid, classified as financing activities				$ 130,882
Number of shares issued and fully paid | shares				360,577
Fair value of finance cost								1,500,000
Fair value was allocated to the warrants								$ 488,149
Expected dividend as percentage, share options granted								0%
Expected volatility, share options granted								66%
Risk free interest rate, share options granted								279%
Option life, share options granted | Segment								5
December senior secured promissory note [member] | Initial public offering [member]
IfrsStatementLineItems [Line Items]
Principal amount rate						50%
December senior secured promissory note [member] | Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Proceeds from borrowings, classified as financing activities	$ 5,000,000
April senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Long term debt					$ 1,650,000
Debt interest rate					8%
Professtional fee					$ 242,750
Effective interest rate					55%
Repayments of borrowings, classified as financing activities				$ 1,650,000
Interest paid, classified as financing activities				$ 71,985
Number of shares issued and fully paid | shares				396,635
Notes maturity date					December 2, 2022
Increase interest rate					15%
Promissory note percentage					10%
Issuance of debt					$ 1,500,000
[custom:FairValueOfCommitmentOfRecognizedFinancingCost]								$ 1,113,036
April senior secured promissory note [member] | Initial public offering [member]
IfrsStatementLineItems [Line Items]
Principal amount rate								100%
April senior secured promissory note [member] | Nonadjusting event [member] | Initial public offering [member]
IfrsStatementLineItems [Line Items]
Proceeds from borrowings, classified as financing activities		$ 5,000,000
Senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Additional forebearance fee			$ 75,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Related Party Transactions
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS Key Management Compensation Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company’s executive officers and Board of Director members. All related party transactions are in the normal course of operations. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES a) Related party transactions with directors, subsequent and former directors and companies and entities over which they have significant influence over: 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Director fees $ 107,168 72,541 $ 54,585 Professional fees 327,370 - 55,625 Share-based compensation $ 128,729 - $ 1,997,611 b) Key management compensation 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Consulting fees $ - $ 270,427 $ 206,507 Salaries 686,615 - - Share-based compensation $ 143,032 $ - $ 2,527,596 c) Accounts payable and accrued liabilities – As of October 31, 2022, $ 33,918 (October 31, 2021 - $ 155,979 ; January 31, 2021 - $ 2,740 ) due to related parties was included in accounts payable and accrued liabilities. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021
Current accrued expenses and other current liabilities	$ 33,918	$ 155,979	$ 2,740

SHARE CAPITAL

SHARE CAPITAL									1 Months Ended						9 Months Ended	12 Months Ended
	Aug. 05, 2022 USD ($) shares $ / shares	Nov. 23, 2020 shares	Jun. 24, 2020 USD ($) $ / shares shares	Jun. 24, 2020 CAD ($)	Feb. 13, 2020 USD ($) $ / shares shares	Feb. 13, 2020 CAD ($)	Feb. 12, 2020 USD ($) $ / shares shares	Feb. 12, 2020 CAD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2020 CAD ($) shares	Aug. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2020 CAD ($) shares	Jul. 31, 2020 USD ($) $ / shares shares	Jul. 31, 2020 CAD ($)	Oct. 31, 2021 USD ($) shares $ / shares	Oct. 31, 2022 USD ($) shares $ / shares	Jan. 31, 2021 USD ($) shares Segment $ / shares	Jan. 31, 2021 USD ($) Segment $ / shares	Sep. 30, 2022 USD ($) shares	Aug. 13, 2022 USD ($) shares	Jul. 29, 2022 shares	Jul. 22, 2022 shares	Jan. 31, 2021 $ / shares	Sep. 30, 2020 $ / shares	Aug. 31, 2020 $ / shares	Aug. 30, 2020 USD ($)	Jul. 31, 2020 $ / shares	Jul. 17, 2020 USD ($) shares	Jun. 30, 2020 shares	Jun. 24, 2020 $ / shares	Feb. 13, 2020 $ / shares shares	Feb. 12, 2020 $ / shares	Jan. 31, 2020 USD ($)
IfrsStatementLineItems [Line Items]
SHARE CAPITAL																12. SHARE CAPITAL a) Share capital Authorized share capital Unlimited Common Shares without par value. Shares outstanding On July 29, 2022, the Company completed a share reorganization (the “Share Reorganization”) to redesignate all Class B shares to common shares and to convert the Class A shares to common shares. The Company also effected a share consolidation on the basis of 1 new share for each 3.86 shares outstanding (the “Consolidation”). Prior to the Share Reorganization and Consolidation, the Company had 6,824,127 Class A and 7,130,223 Class B common shares issued and outstanding. Immediately following the Share Reorganization and Consolidation, the Company had 3,615,116 common shares outstanding. Except where otherwise indicated, all historical share numbers and per share amounts have been adjusted on a retroactive basis to reflect following the Share Reorganization and Consolidation. Year ended October 31, 2022: On July 22, 2022, the Company cancelled 316,023 On August 5, 2022, the Company closed its IPO of 3,728,549 units at $ 4.16 per unit, each unit consists of one share of common stock and one warrant, with an exercise price of $ 4.16 per share. The gross proceeds of the offering were $ 15,510,764 . The fair value of the warrants was determined to be $ 5,047,704 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: expected dividend yield - 0 %, expected volatility - 66 %, risk-free interest rate – 2.79 % and an expected remaining life - 5 years. In connection with the IPO, the Company paid share issuance costs of $ 1,840,861 consisting of $ 1,085,753 in underwriting fees, $ 500,000 in legal fees and $ 255,108 in other related expenses. In addition, the Company issued 262,841 warrants to the underwriter exercisable at $ 5.20 until August 4, 2027. The fair value of the underwriter warrants was estimated to be $ 318,581 using the Black-Scholes Options Pricing Model using the following assumptions: expected dividend yield - 0 %, expected volatility - 66 %, risk-free interest rate – 2.92 % and an expected remaining life - 5 years (Note 13). On August 5, 2022, the Company issued 757,212 shares with a fair value of $ 2,124,886 as part of the repayment of its December Senior Secured Promissory Notes and April Senior Secured Promissory Notes. On September 30, 2022, the Company issued 50,000 shares with a fair value of $ 140,310 to a consultant for marketing services. Year ended October 31, 2021: On August 13, 2021, the Company issued 2,277 12,658 Year ended January 31, 2021: On February 12, 2020, the Company issued 108,233 452,694 On February 12, 2020, the Company issued 36,078 5.56 4.17 200,000 150,898 BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 12. SHARE CAPITAL (continued) On February 13, 2020, the Company issued 90,194 5.56 4.17 525,000 377,239 On June 24, 2020, the Company issued 508,696 2,074,902 On June 24, 2020, the Company issued 112,743 2.20 1.66 250,000 183,945 459,863 275,918 On July 17, 2020, the Company issued 489,026 1,997,611 In July and August 2020, the Company completed a private placement of 535,491 2.32 1.66 1,240,198 746,365 3.47 2.59 178,955 0 100 0.28 2.95 In August and September 2020, the Company completed a brokered private placement of 756,230 6.95 5.17 5,311,684 3,217,886 10.42 7.80 821,346 400,083 179,434 236,073 123,981 0 100 0.30 2.84 a) Options The Company has established a stock option plan for its directors, officers, employees, and consultants under which the Company may grant options (each, an “Option”) from time to time to acquire Shares. The exercise price of each Option shall be determined by the Board of Directors. Options may be granted for a maximum term of five years During the year ended January 31, 2021, the Company granted 80,181 options exercisable at CAD$ 6.95 until November 9, 2025. 40,876 of the options vested on November 23, 2020, with the remaining options vesting on November 23, 2021. The fair value of the options was determined to be $ 145,933 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: expected dividend yield - 0 %, expected volatility - 100 %, risk-free interest rate - 0.25 % and an expected remaining life - 5 years. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 12. SHARE CAPITAL (continued) During the year ended October 31, 2022, the Company recognized share-based compensation expense of $ 7,861 92,276 145,933 As at October 31, 2022, October 31, 2021, and January 31, 2021, 80,181 options with an exercise price of CAD$ 6.90 , expiring on November 9, 2025, were outstanding and exercisable. b) Warrants During the year ended October 31, 2022, the Company granted 360,577 4.16 August 4, 2027 During the year ended October 31, 2022, the Company issued 3,728,549 warrants of the Company as part of its IPO. These warrants have an exercise price of $ 4.16 , expiring on August 4, 2027 . These warrants have a cashless exercise provision and are accounted for as derivative liabilities, see Note 13. During the year ended October 31, 2022, the Company issued 262,841 warrants of the Company to the underwriter of its IPO. These warrants have an exercise price of $ 5.20 , expiring on August 4, 2027 . During the year ended January 31, 2021, in connection with a private placement, the Company issued 267,745 warrants with an exercise price of CAD$ 3.47 ($ 2.66 ) per warrant with an expiry date of twenty-four months from the Liquidity Event. As the warrants have an exercise price denominated in a currency other than the Company’s functional currency, they are derivative financial instruments measured at fair value at the end of each reporting period see Note 13. 661 broker warrants with the same terms were also issued. During the year ended January 31, 2021, in connection with a private placement, the Company issued 401,354 warrants with an exercise price of CAD$ 10.42 ($ 7.80 ) per warrant with an expiry date of twenty-four months from the Liquidity Event. As the warrants have an exercise price denominated in a currency other than the Company’s functional currency, they are derivative financial instruments measured at fair value at the end of each reporting period, see Note 13. 60,498 broker warrants with the same terms were also issued. Continuity of the warrants issued and outstanding as follows: SUMMARY OF WARRANTS ISSUED AND OUTSTANDING Number of warrants Weighted average exercise price Outstanding, January 31, 2020 - $ - Granted 730,258 7.87 Outstanding, January 31, 2021 and October 31, 2021 730,258 $ 7.87 Granted - - Outstanding, January 31, 2021 and October 31, 2021 730,258 $ 7.87 Granted 4,351,967 4.22 Outstanding, October 31, 2022 5,082,225 $ 4.75 The following table discloses the number of warrants outstanding as at October 31, 2022: SUMMARY OF WARRANTS OUTSTANDING Number of warrants Price Expiry date 181,869 CAD$ 3.47 June 30, 2023 86,537 $ 2.85 June 30, 2023 461,852 CAD$ 10.42 June 30, 2023 4,089,126 $ 4.16 August 4, 2027 262,841 $ 5.20 August 4, 2027 5,082,225 As at October 31, 2022, the weighted average life remaining of warrants outstanding is 4.17 BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 12. SHARE CAPITAL (continued) c) Restricted Share Awards On June 30, 2022, the Company issued 492,228 2.85 During the year ended October 31, 2022, the Company recognized share-based compensation expense of $ 271,761 for the vesting of RSUs (9 months ended October 31, 2021 - $ nil , 12 months ended January 31, 2021 - $ nil SUMMARY OF RESTRICTED SHARE AWARDS Number of RSUs Weighted average grant date fair value Outstanding, January 31, 2021 and October 31, 2021 - $ - Granted 492,228 2.85 Outstanding, October 31, 2022 492,228 $ 2.85 Vested, October 31, 2022 - $ -
Number of shares outstanding																					3.86
Number of shares issued			112,743		90,194		36,078																								90,194
Par value per share | (per share)			$ 1.66		$ 4.17		$ 4.17																							$ 2.20	$ 5.56	$ 5.56
Exercise price of outstanding share options | $ / shares	$ 4.16
Proceeds from share issuance | $	$ 15,510,764
Fair value of warrants | $	5,047,704														$ 1,582,977	$ 1,242,580	$ 1,490,059	$ 1,490,059
Expected dividend yield																0%	0%
Expected volatility																100%	100%
Risk-free interest rate																1.11%	0.25%
Expected remaining life																	5 years
Payments for share issue costs | $	1,840,861															$ 1,840,861
Underwriting fees | $	1,085,753
Legal fee | $	500,000
Other expenses, by nature | $	$ 255,108
Number of warrants, granted																4,351,967	730,258
Share-based compensation | $			$ 459,863
Proceeds from issue of shares			183,945	$ 250,000	$ 377,239	$ 525,000	$ 150,898	$ 200,000
Consulting fees | $			275,918
Options granted term																5 years
Number of share options granted in share-based payment arrangement																	80,181
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares																		$ 6.95
Options vested		40,876
Weighted average fair value at measurement date, share options granted | $																	$ 145,933	$ 145,933
Number of share options outstanding in share-based payment arrangement | Segment																	80,181	80,181
Weighted average exercise price of share options exercisable in share-based payment arrangement | $ / shares																							$ 6.90
Granted price | $ / shares																$ 4.22	$ 7.87
Weighted average life remaining of warrants outstanding																4 years 2 months 1 day
Vesting options [member]
IfrsStatementLineItems [Line Items]
Share-based compensation | $															$ 92,276	$ 7,861	$ 145,933
Restricted share awards [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																492,228
Share-based compensation | $																$ 271,761
Granted price | $ / shares																$ 2.85
Consultant [member]
IfrsStatementLineItems [Line Items]
Number of shares issued																			50,000	2,277
Share-based compensation | $																			$ 140,310	$ 12,658
December and april senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Number of shares issued	757,212
Share-based compensation | $	$ 2,124,886
December senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Expected dividend yield																0%
Expected volatility																66%
Risk-free interest rate																279%
IPO [member]
IfrsStatementLineItems [Line Items]
Number of shares issued	3,728,549
Par value per share | $ / shares	$ 4.16
Warrant reserve [member]
IfrsStatementLineItems [Line Items]
Expected dividend yield	0%										0%	0%	0%	0%
Expected volatility	66%										100%	100%	100%	100%
Risk-free interest rate	2.79%										0.28%	0.28%	0.28%	0.28%
Expected remaining life	5 years										2 years 11 months 12 days	2 years 11 months 12 days	2 years 11 months 12 days	2 years 11 months 12 days
Number of warrants, granted	262,841																267,745
Exercise price | (per share)	$ 5.20										$ 2.59		$ 2.59												$ 3.47		$ 3.47
Granted price | (per share)																	$ 2.66	$ 3.47
Warrants expiry date																Aug. 04, 2027
Warrant reserve [member] | December senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																360,577
Granted price | $ / shares																$ 4.16
Underwriter warrants [member]
IfrsStatementLineItems [Line Items]
Expected dividend yield	0%
Expected volatility	66%
Risk-free interest rate	2.92%
Expected remaining life	5 years
Fair value of warrant | $	$ 318,581
Private placement [member]
IfrsStatementLineItems [Line Items]
Number of shares issued											535,491
Private placement [member]
IfrsStatementLineItems [Line Items]
Number of shares issued													535,491
Par value per share | (per share)											$ 1.66		$ 1.66												2.32		$ 2.32
Fair value of warrants | $											$ 178,955		$ 178,955
Proceeds from issue of shares											$ 746,365	$ 1,240,198	$ 746,365	$ 1,240,198
Brokered private placement [member]
IfrsStatementLineItems [Line Items]
Number of shares issued									756,230		756,230
Par value per share | (per share)									$ 5.17		$ 5.17													$ 6.95	6.95
Proceeds from share issuance									$ 3,217,886	$ 5,311,684	$ 3,217,886	$ 5,311,684
Fair value of warrants | $									821,346																	$ 821,346
Paid finders fees | $									$ 400,083		$ 400,083
Number of shares issued, fees									179,434	179,434	179,434	179,434
Brokered warrant [member]
IfrsStatementLineItems [Line Items]
Number of shares issued									236,073		236,073
Fair value of warrants | $									$ 123,981		$ 123,981
Expected dividend yield									0%	0%	0%	0%
Expected volatility									100%	100%	100%	100%
Risk-free interest rate									0.30%	0.30%	0.30%	0.30%
Expected remaining life									2 years 10 months 2 days	2 years 10 months 2 days	2 years 10 months 2 days	2 years 10 months 2 days
Exercise price | (per share)									$ 7.80		$ 7.80													$ 10.42	$ 10.42
Broker warrants [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																	661
Warrant One [Member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																	401,354
Granted price | (per share)																	$ 7.80	$ 10.42
Broker warrant one [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																	60,498
Director [Member]
IfrsStatementLineItems [Line Items]
Number of shares, cancelled																						316,023
Number of shares issued																												489,026
Share-based compensation | $																												$ 1,997,611
Director [Member] | Restricted share awards [member]
IfrsStatementLineItems [Line Items]
Number of shares issued																													492,228
Chief Executive Officer [Member]
IfrsStatementLineItems [Line Items]
Number of shares issued							108,233
Share-based compensation | $			$ 2,074,902				$ 452,694
Number of shares issued, services			508,696
Class A shares [member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding																					6,824,127
Class B shares [member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding																					7,130,223
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding																					3,615,116
IPO [member] | Warrant reserve [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																3,728,549
Granted price | $ / shares																$ 4.16
Underwriters [member] | Warrant reserve [member]
IfrsStatementLineItems [Line Items]
Number of warrants, granted																262,841
Granted price | $ / shares																$ 5.20

DERIVATIVE WARRANT LIABILITY

DERIVATIVE WARRANT LIABILITY		1 Months Ended	12 Months Ended
	Jul. 29, 2022 USD ($) shares $ / shares	Aug. 31, 2022 USD ($)	Oct. 31, 2022 USD ($) shares Segment $ / shares	Oct. 31, 2021 USD ($) shares	Jan. 31, 2021 shares	Oct. 31, 2022 $ / shares	Oct. 31, 2021 $ / shares	Sep. 30, 2020 shares $ / shares	Sep. 30, 2020 shares $ / shares	Aug. 31, 2020 shares $ / shares	Aug. 31, 2020 shares $ / shares	Jul. 31, 2020 shares $ / shares	Jul. 31, 2020 shares $ / shares	Jan. 31, 2020 shares
IfrsStatementLineItems [Line Items]
DERIVATIVE WARRANT LIABILITY			13. DERIVATIVE WARRANT LIABILITY 267,745 3.47 2.66 86,537 2.66 136,047 2.85 0 100 2.92 2.01 181,208 30,469 1.49 0 72 3.90 1.76 818,871 5.64 0 100 1.11 1.66 In August and September 2020, in connection with a private placement, the Company issued 382,246 warrants with an exercise price of CAD$ 10.42 ($ 7.80 ) per warrant with an expiry date of twenty-four months from the Liquidity Event. As the warrants have an exercise price denominated in a currency other than the Company’s functional currency, they are derivative financial instrument measured at fair value at the end of each reporting period. As at October 31, 2022, the fair value of the warrants was determined to be $ 8,655 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: fair value of the underlying stock – CAD$ 1.49 , expected dividend yield – 0 %, expected volatility – 72 %, risk-free interest rate – 3.90 % and an expected remaining life – 1.76 years. (2021 - $ 764,106 based on the Black-Scholes Option Pricing Model using the following assumptions: fair value of the underlying stock – CAD$ 5.64 , expected dividend yield – 0 %, expected volatility – 100 %, risk-free interest rate – 1.11 % and an expected remaining life – 1.66 years). BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 13. DERIVATIVE WARRANT LIABILITY (continued) In August 2022, in connection with the units issued as part of the Company’s IPO, the Company issued 3,728,549 warrants with an exercise price of $ 4.16 per warrant with an expiry date of five years from the date of issuance. The warrants contain a cashless exercise provision which enables the holder to receive common shares equal to the fair value of the warrants based on the number of warrants to be exercise multiplied by the fair value of the common shares less the exercise price with the difference divided by the fair value of the share. If a warrant holder exercises this option, there will be variability in the number of shares issued, therefore they are a derivative financial instrument measured at fair value at the end of each reporting period. As at October 31, 2022, the fair value of the warrants was determined to be $ 1,097,323 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: fair value of the underlying stock – $ 1.09 , expected dividend yield – 0 %, expected volatility – 67 %, risk-free interest rate – 3.43 % and an expected remaining life – 4.76 years. In August 2022, in connection with the units issued as part of its December Senior Secured Promissory Notes, the Company issued 360,577 warrants with an exercise price of $ 4.16 per warrant with an expiry date of five years from the date of issuance. The warrants contain a cashless exercise provision which enables the holder to receive common shares equal to the fair value of the warrants based on the number of warrants to be exercise multiplied by the fair value of the common shares less the exercise price with the difference divided by the fair value of the share. If a warrant holder exercises this option, there will be variability in the number of shares issued, therefore they are a derivative financial instrument measured at fair value at the end of each reporting period. At issuance, the fair value of the warrants was determined to be $ 488,147 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: fair value of the underlying stock – $ 2.81 , expected dividend yield – 0 %, expected volatility – 66 %, rick-free interest rate – 2.79 5 years. 106,119 and was estimated using the Black-Scholes Options Pricing Model using the following assumptions: fair value of the underlying stock – $ 1.09 , expected dividend yield – 0 %, expected volatility – 67 3.43 % and an expected remaining life – 4.76 years. The following is a continuity of the Company’s derivative warrant liability: SCHEDULE OF DERIVATIVE WARRANT LIABILITY Balance, January 31, 2020 $ - Issued during the period 953,850 Change in fair value of derivative 536,209 Balance, January 31, 2021 $ 1,490,059 Change in fair value of derivative 92,918 Balance, October 31, 2021 $ 1,582,977 Beginning balance $ 1,582,977 Issued during the period 5,535,852 Change in fair value of derivative (5,740,202 ) Derecognition of warrant derivative (136,047 ) Balance, October 31, 2022 $ 1,242,580 Ending b alance $ 1,242,580 BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021
Number of warrants, issued | shares			5,082,225	730,258	730,258
Derecognition of warrant derivative			$ (136,047)
Derivative fair value share price | $ / shares						$ 5.64
Expected dividend yield			0%		0%
Expected volatility			100%		100%
Risk-free interest rate			1.11%		0.25%
Expected remaining life			1 year 7 months 28 days
Fair value of warrants liability			$ 818,871
Warrants [member]
IfrsStatementLineItems [Line Items]
Number of warrants, issued	86,537		181,208							267,745	267,745	267,745	267,745
Warrant exercise price | (per share)	$ 2.66									$ 2.66	$ 3.47	$ 2.66	$ 3.47
Derecognition of warrant derivative	$ 136,047
Derivative fair value share price | (per share)	$ 2.85					1.49
Expected dividend yield	0%		0%
Expected volatility	100%		72%
Risk-free interest rate	2.92%		3.90%
Expected remaining life	2 years 3 days		1 year 9 months 3 days
Fair value of warrants liability			$ 30,469
Warrants [member] | Private placement [member]
IfrsStatementLineItems [Line Items]
Number of warrants, issued | shares								382,246	382,246
Warrant exercise price | (per share)								$ 7.80	$ 10.42
Derivative fair value share price | $ / shares						$ 1.49	$ 5.64
Expected dividend yield			0%	0%
Expected volatility			72%	100%
Risk-free interest rate			3.90%	1.11%
Expected remaining life			1 year 9 months 3 days	1 year 7 months 28 days
Fair value of warrants liability			$ 8,655	$ 764,106
Warrants [member] | Initial public offering [member]
IfrsStatementLineItems [Line Items]
Number of warrants, issued | shares										3,728,549	3,728,549
Warrant exercise price | $ / shares										$ 4.16
Derivative fair value share price | $ / shares			$ 1.09
Expected dividend yield			0%
Expected volatility			67%
Risk-free interest rate		2.79%	3.43%
Expected remaining life			4 years 9 months 3 days
Fair value of warrant			$ 1,097,323
Warrants [member] | Initial public offering [member] | Underwriter [member]
IfrsStatementLineItems [Line Items]
Derivative fair value share price | $ / shares			$ 1.09
Expected dividend yield			0%
Risk-free interest rate			3.43%
Expected remaining life			4 years 9 months 3 days
Fair value of warrants liability			$ 106,119
Expected volatility			67%
Warrants [member] | December senior secured promissory notes [member]
IfrsStatementLineItems [Line Items]
Number of warrants, issued | shares										360,577	360,577
Warrant exercise price | $ / shares										$ 4.16
Derivative fair value share price | $ / shares			$ 2.81
Expected dividend yield			0%
Expected volatility			66%
Expected remaining life			5 years
Fair value of warrant		$ 488,147

OTHER LOSS

OTHER LOSS - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Other Loss
OTHER LOSS		14. OTHER LOSS During the year ended October 31, 2022, the Company fell victim to a cyber-scam that resulted in the Company making an inappropriate payment of $ 166,150
Other loss		$ 166,150

FINANCIAL INSTRUMENT RISK MANAG

FINANCIAL INSTRUMENT RISK MANAGEMENT	12 Months Ended
	Oct. 31, 2022 USD ($)
Financial Instrument Risk Management
FINANCIAL INSTRUMENT RISK MANAGEMENT	15. FINANCIAL INSTRUMENT RISK MANAGEMENT Classification of financial instruments Financial assets included in the statement of financial position are as follows: SCHEDULE OF FINANCIAL ASSETS Level in fair October 31, 2022 October 31, 2021 January 31, 2021 Amortized cost: Cash $ 72,921 $ 14,530 $ 692,647 Term deposit 18,506 - - Accounts receivable 175,256 161,047 81,159 Financial assets $ 266,683 $ 175,577 $ 773,806 Financial liabilities included in the statement of financial position are as follows: SCHEDULE OF FINANCIAL LIABILITIES Level in fair October 31, 2022 October 31, 2021 January 31, 2021 Amortized cost: Accounts payable and accrued expenses $ 1,345,288 $ 3,366,062 $ 308,719 Loans payable - 27,144 17,580 FVTPL: Warrant derivative liability Level 3 1,242,580 1,582,977 1,490,059 Financial liabilities $ 2,587,868 $ 4,976,183 $ 1,816,358 Fair value Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; ● Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and ● Level 3 – Inputs that are not based on observable market data. The carrying value of the Company’s cash, term deposits, accounts receivable and accounts payable and accrued liabilities as at approximate their fair value due to their short terms to maturity. The following table shows the valuation techniques used in measuring Level 3 fair values for the derivative liability as well as the significant unobservable inputs used. Type Valuation technique Key inputs Inter-relationship between significant inputs and fair value measurement Warrant derivative liability The fair value of the warrant derivative liability at initial recognition and at period-end has been calculated using the Black Scholes option pricing model. Key observable inputs ● Share price ● Risk free interest rate ● Dividend yield Key unobservable inputs ● Expected volatility The estimated fair value would increase (decrease) if: ● The share price was higher (lower) ● The risk-free interest rate was higher (lower) ● The dividend yield was lower (higher) ● The expected volatility was higher (lower) BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 15. FINANCIAL INSTRUMENT RISK MANAGEMENT (continued) For the fair values of the derivative liability, reasonably possible changes to the expected volatility, the most significant unobservable input would have the following effects: SCHEDULE OF UNOBSERVABLE INPUTS LIABILITY Unobservable Inputs Change Impact on comprehensive loss 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Volatility 20 % $ 537,641 $ 258,303 $ 144,370 The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. Credit risk The Company’s principal financial assets are cash and trade accounts receivable. The Company’s credit risk is primarily concentrated in its cash which is held with institutions with a high credit worthiness. Credit risk is not concentrated with any particular customer. The Company’s accounts receivable consists primarily of GST receivable. The Company’s maximum credit risk exposure is $ 175,256 . Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company’s normal operating requirements on an ongoing basis. Historically, the Company’s primary source of funding has been the issuance of equity securities for cash, primarily through the issuance of preferred shares. The Company’s access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. The following is an analysis of the contractual maturities of the Company’s financial liabilities as at October 31, 2022: SCHEDULE OF ANALYSIS OF CONTRACTUAL MATURITIES FINANCIAL LIABILITIES Within one year Between one More than five Accounts payable and accrued expenses $ 1,345,288 $ - $ - Foreign exchange risk Foreign currency risk arises from fluctuations in foreign currencies versus the United States dollar that could adversely affect reported balances and transactions denominated in those currencies. As at October 31, 2022, a portion of the Company’s financial assets are held in Canadian dollars. The Company’s objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by transacting, to the greatest extent possible, with third parties in United States dollars. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant at this point in time. The Company is not exposed to any material foreign currency risk. Interest rate risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to any material interest rate risk. Capital Management In the management of capital, the Company includes components of shareholders’ equity. The Company aims to manage its capital resources to ensure financial strength and to maximize its financial flexibility by maintaining strong liquidity and by utilizing alternative sources of capital including equity, debt and bank loans or lines of credit to fund continued growth. The Company sets the amount of capital in proportion to risk and based on the availability of funding sources. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. Issuance of equity has been the primary source of capital to date. Additional debt and/or equity financing may be pursued in future as deemed appropriate to balance debt and equity. To maintain or adjust the capital structure, the Company may issue new shares, take on additional debt or sell assets to reduce debt. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021
Maximum credit risk	$ 175,256

SEGMENTED INFORMATION

SEGMENTED INFORMATION	12 Months Ended
	Oct. 31, 2022
Segmented Information
SEGMENTED INFORMATION	16. SEGMENTED INFORMATION The Company’s breakdown of sales by geographical region is as follows: SCHEDULE OF SALES BY GEOGRAPHICAL REGION 12-months ended 9-months ended 12-months ended United States of America $ 1,656,215 $ 1,238,259 $ 512,094 Canada 976,227 727,182 389,068 Revenue $ 2,632,442 $ 1,965,441 $ 901,162 The Company’s breakdown of sales by product segment is as follows: SCHEDULE OF SALES BY PRODUCT SEGMENT 12-months ended 9-months ended 12-months ended Devices $ 1,663,939 $ 1,367,778 $ 817,778 Consumables 968,503 597,663 83,384 Revenue $ 2,632,442 $ 1,965,441 $ 901,162

INCOME TAXES

INCOME TAXES - USD ($)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
INCOME TAXES	17. INCOME TAXES SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSES (RECOVERY) 12-months ended 9-months ended 12-months ended Net loss $ (8,765,271 ) $ (4,211,271 ) $ (8,890,431 ) Statutory income tax rate 26.50 % 26.50 % 26.50 % Income tax benefit computed at the statutory tax rate (2,322,797 ) (1,115,987 ) (2,355,964 ) Non-deductible items (1,375,505 ) 62,336 1,457,569 Financing fees charged to equity (487,828 ) - (106,022 ) Change in tax assets not recognized 4,186,130 1,053,651 1,004,417 Income tax recovery $ - $ - $ - The Company had the following unrecognized deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSET AND LIABILITIES October 31, 2022 October 31, 2021 January 31, 2021 Non-capital losses $ 6,357,780 $ 2,541,736 $ 1,467,401 Equipment 1,549 520 - Share issuance costs 432,671 63,613 84,818 Total 6,792,000 2,605,869 1,552,219 Unrecognized deferred tax assets (6,792,000 ) (2,605,869 ) (1,552,219 ) Net deferred tax assets $ - $ - $ - As at October 31, 2022, the Company had approximately $ 24,000,000 in non-capital losses expiring as between 2038 and 2042.
[custom:NoncapitalLosses-0]	$ 6,357,780	$ 2,541,736	$ 1,467,401
Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
[custom:NoncapitalLosses-0]	$ 24,000,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS			9 Months Ended	12 Months Ended
	Dec. 09, 2022 USD ($) $ / shares shares	Aug. 05, 2022 USD ($)	Oct. 31, 2021 USD ($)	Oct. 31, 2022 USD ($)	Aug. 31, 2020 $ / shares	Aug. 31, 2020 $ / shares	Jul. 31, 2020 $ / shares shares	Jul. 31, 2020 $ / shares shares	Jun. 24, 2020 $ / shares shares	Jun. 24, 2020 $ / shares shares	Feb. 13, 2020 $ / shares shares	Feb. 13, 2020 $ / shares shares	Feb. 12, 2020 $ / shares shares	Feb. 12, 2020 $ / shares shares
IfrsStatementLineItems [Line Items]
SUBSEQUENT EVENTS				18. SUBSEQUENT EVENTS On December 9, 2022, the Company closed a private placement pursuant to a securities purchase agreement with institutional investors. The Company issued 2,966,667 1,950,001 0.60 2,948,050 0.001 0.60 5.5 In connection with the private placement, the Company paid share issuance costs of $ 623,750 295,000 132,500 196,250
Number of shares issued | shares									112,743	112,743	90,194	90,194	36,078	36,078
Par value per share | (per share)									$ 1.66	$ 2.20	$ 4.17	$ 5.56	$ 4.17	$ 5.56
Proceeds from issuing shares		$ 15,510,764
Payments for share issue costs		1,840,861		$ 1,840,861
Underwriting fees		1,085,753
Legal fees		500,000
Other expenses, by nature		$ 255,108
Private placement [member]
IfrsStatementLineItems [Line Items]
Number of shares issued | shares							535,491	535,491
Par value per share | (per share)					$ 1.66	$ 2.32	$ 1.66	$ 2.32
Private placement [member] | Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Number of shares issued | shares	2,966,667
Number of shares pre-funded issued | shares	1,950,001
Par value per share | $ / shares	$ 0.60
Proceeds from issuing shares	$ 2,948,050
Payments for share issue costs	623,750
Underwriting fees	295,000
Legal fees	132,500
Other expenses, by nature	$ 196,250
Warrant reserve [member] | Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Par value per share | $ / shares	$ 0.001
Warrant term	5 years 6 months
Warrant reserve one [member] | Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Par value per share | $ / shares	$ 0.60

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (Policies)	12 Months Ended
	Oct. 31, 2022
Summary Of Significant Accounting Policies And Use Of Estimates And Judgments
Revenue recognition	Revenue recognition The Company’s revenue is generated from the sale of finished product to customers. Those sales predominantly contain a single performance obligation and revenue is recognized at a single point in time when ownership, risks and rewards transfer, which is typically the date of receipt by the customer. When the Company has collected payment from a customer, but the product is in transit, the Company will defer the recognition of the product sale in revenues until such time the product is delivered to the customer. A provision for payment discounts and product return allowances is recorded as a reduction of sales in the same period the revenue is recognized. The revenue recorded is presented net of sales and other taxes the Company collect on behalf of governmental authorities.
Foreign currency translation	Foreign currency translation The functional currency of each entity is determined using the currency of the primary economic environment in which that entity operates. The Company’s financial statements are presented in U.S. dollars. The functional currency for the Company is the U.S. dollar. Foreign currency transactions are translated into the functional currency of the Company, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the remeasurement of monetary items denominated in foreign currency at year end exchange rates are recognized in the statement of loss and comprehensive loss. Non-monetary items are not retranslated at year end and are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value which are translated using the exchange rates at the date when fair value was determined.
Inventory	Inventory Inventory consists entirely of finished goods and is valued at the lower of cost or net realizable value. The cost of inventory is maintained using the average-cost method. The net realizable value of finished goods is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods inventory is based on landed cost, which includes all costs incurred to bring inventory to the Company’s distribution centers including product costs, inbound freight and duty. If the Company determines that the estimated net realizable value of its inventory is less than the carrying value of such inventory, it records a charge to cost of goods sold.
Property and equipment	Property and equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred; cost of major additions and betterments are capitalized. Upon sale or other disposition of a depreciable asset, cost and accumulated depreciation are removed from property and equipment and any gain or loss is reflected as a gain or loss from operations. The estimated useful life of the computers and software is 3 years BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued)
Intangible assets	Intangible assets Purchased intangible assets are recognized as assets in accordance with IAS 38 – Intangible Assets, where it is probable that the use of the asset will generate future economic benefits and where the cost of the asset can be determined reliably. Intangible assets acquired are initially recognized at cost of purchase and are subsequently carried at cost less accumulated amortization, if applicable, and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. All finite-lived intangible assets are stated at cost less accumulated impairment.
Impairment of assets	Impairment of assets The Company performs impairment tests on its long-lived assets, including property and equipment and intangible assets, when new events or circumstances occur, or when new information becomes available relating to their recoverability. When the recoverable amount of each separately identifiable asset or cash generating unit (“CGU”) is less than its carrying value, the asset or CGU’s assets are written down to their recoverable amount with the impairment loss charged against profit or loss. A reversal of the impairment loss in a subsequent period will be charged against profit or loss if there is a significant reversal of the circumstances that caused the original impairment. The impairment will be reversed up to the amount of depreciated carrying value that would have otherwise occurred if the impairment loss had not occurred.
Leases	Leases The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. Lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. Lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments or a change in the assessment of an option to purchase the underlying asset. The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. As at October 31, 2022, October 31, 2021 and January 31, 2021, the Company did not have any leases in place. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued)
Research and development costs	Research and development costs Expenditure on research activities, undertaken with the prospect of gaining new technical knowledge and understanding, is recognized in profit or loss as incurred. During the year ended October 31, 2022, $ 96,431 (Nine months ended October 31, 2021 - $ Nil Nil of research and development costs were recorded in the Statement of Comprehensive Loss. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred. Research and development costs incurred subsequent to the acquisition of externally acquired intangible assets and on internally generated intangible assets are accounted for as research and development costs. As at October 31, 2022, October 31, 2021 and January 31, 2021, the Company has not capitalized any research and development costs.
Financial instruments	Financial instruments (a) Classification The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. (b) Measurement Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of loss and comprehensive loss in the period in which they arise. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Debt investments at FVTOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity investments at FVTOCI These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. (c) Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of loss and comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. (d) Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. Income taxes Current income tax: Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred tax: Deferred tax is recognized on temporary differences at the reporting date arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that future taxable income will be available to allow all or part of the temporary differences to be utilized. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted and are expected to apply by the end of the reporting period. Deferred tax assets and deferred income tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Loss per share	Loss per share Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. For all periods presented, the loss attributable to common shareholders equals the reported loss attributable to owners of the Company.
Share capital	Share capital Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares are recognized as a deduction from shareholders’ equity, net of tax. In the event that the financing is not completed, these costs are expensed to profit or loss. The Company may engage in equity financing transactions to obtain the funds necessary to continue operations. These equity financing transactions may involve issuance of common shares or units. A unit comprises a certain number of common shares and a certain number of share purchase warrants. Depending on the terms and conditions of each financing agreement, the warrants are exercisable into additional common shares prior to expiry at a price stipulated by the agreement. Warrants that are part of units are assigned a residual value if the unit is issued at a price exceeding the market price of underlying share at the time of issuance otherwise the warrants are assigned no value and included in share capital with the common shares that are concurrently issued. Warrants that are issued as payment for an agency fee or other transactions costs are accounted for as share-based payment transaction costs. Warrants that are exercisable in currencies other than the Company’s functional currency of U.S. dollars are considered to be derivative financial instruments. The Company presents such warrants as derivative liabilities on the balance sheet and measures them at fair value at the end of each reporting period. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued)
Critical accounting estimates and significant management judgments	Critical accounting estimates and significant management judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Fair value measurement of broker warrants and warrant derivative The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date on which they are granted. When the fair value of financial assets and financial liabilities recorded in the Statements of Financial Position cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques. Estimating fair value for broker warrants and the warrant derivative requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires the determination of the most appropriate inputs to the valuation model including the expected remaining life of the broker warrants and the warrant derivative, fair value of the underlying stock, volatility, risk-free interest rate and dividend yield and making assumptions about them. Where possible the Company will utilize contractual and publicly available information to determine valuation model inputs. If no such information is available, the Company will use historical performance and if required, the Company will make estimations based on the best information available. Expected remaining life is determined using the information in the warrant terms, fair value of the underlying stock is determined based the most recently completed financing, volatility is estimated based on market data and industry assessment, risk-free interest rate is determined based on central bank rates for a similar period to the expected remaining life and dividend yield is estimated using the Company’s past performance and future expectations. The assumptions and models used for estimating fair value for broker warrants and the warrant derivative are disclosed in Note 12. These are either classified as equity instruments or derivative liabilities subject to whether the exercise price is fixed or variable. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. BRUUSH ORAL CARE INC. NOTES TO THE FINANCIAL STATEMENTS (Expressed in U.S. dollars) Twelve months ended October 31, 2022, nine months ended October 31, 2021 and twelve months ended January 31, 2021 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES AND JUDGMENTS (continued) Income taxes The Company recognizes the tax benefit from an uncertain tax position only if it is probable that the tax position will be sustained based on its technical merits. The Company measures and record the tax benefits from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s estimated liabilities related to these matters are adjusted in the period in which the uncertain tax position is effectively settled, the statute of limitations for examination expires or when additional information becomes available. The amount and timing of future taxable income for unrecognized tax benefits requires the use of assumptions and significant judgement to estimate the exposures associated with our various filing positions. The Company has not recognized the value of any deferred tax assets in its statements of financial position. Although the Company believes that the judgements and estimates made are reasonable, actual results could differ and resulting adjustments could materially affect our effective income tax rate and income tax provision. Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: - The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; - The determination of the Company’s functional currency; and - Whether there are indicators of impairment of the Company’s long-lived assets.

ACCOUNTS AND OTHER RECEIVABLES

ACCOUNTS AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Oct. 31, 2022
Accounts And Other Receivables
SUMMARY OF ACCOUNTS AND OTHER RECEIVABLES	SUMMARY OF ACCOUNTS AND OTHER RECEIVABLES October 31, 2022 October 31, 2021 January 31, 2021 Trade receivables $ 103,471 $ 36,734 $ 7,206 Sales taxes receivable 71,785 124,313 73,953 Total $ 175,256 $ 161,047 $ 81,159

PREPAID EXPENSES AND DEPOSITS (

PREPAID EXPENSES AND DEPOSITS (Tables)	12 Months Ended
	Oct. 31, 2022
Prepaid Expenses And Deposits
SUMMARY OF PREPAID EXPENSES AND DEPOSITS	SUMMARY OF PREPAID EXPENSES AND DEPOSITS October 31, 2022 October 31, 2021 January 31, 2021 Prepaid expenses $ 191,322 $ 18,246 $ 7,067 Deposits on inventory 475,458 56,261 111,302 Deposits 10,694 7,067 - Total $ 677,474 $ 81,574 $ 118,369

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Oct. 31, 2022
Accounts Payable And Accrued Liabilities
SUMMARY OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	SUMMARY OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES October 31, 2022 October 31, 2022 January 31, 2021 Accounts payable $ 909,438 $ 2,299,177 $ 236,806 Accrued liabilities 435,850 1,066,885 71,913 Total $ 1,345,288 $ 3,366,062 $ 308,719

SENIOR SECURED PROMISSORY NOT_2

SENIOR SECURED PROMISSORY NOTES (Tables)	12 Months Ended
	Oct. 31, 2022
Senior Secured Promissory Notes
SCHEDULE OF SENIOR SECURED PROMISSORY NOTES	A continuity of the senior secured promissory notes below: SCHEDULE OF SENIOR SECURED PROMISSORY NOTES December Senior Secured Promissory Notes April Senior Secured Promissory Notes Total Balance, January 31, 2021 and October 31, 2021 $ - $ - $ - Additions 3,000,000 1,650,000 4,650,000 Discount - (150,000 ) (150,000 ) Transaction costs (396,500 ) (242,750 ) (639,250 ) Accretion 527,382 464,735 992,117 Repayment (3,130,882 ) (1,721,985 ) (4,852,867 ) Balance, October 31, 2022 $ - $ - $ -

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Oct. 31, 2022
Related Party Transactions
SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES	SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES a) Related party transactions with directors, subsequent and former directors and companies and entities over which they have significant influence over: 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Director fees $ 107,168 72,541 $ 54,585 Professional fees 327,370 - 55,625 Share-based compensation $ 128,729 - $ 1,997,611 b) Key management compensation 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Consulting fees $ - $ 270,427 $ 206,507 Salaries 686,615 - - Share-based compensation $ 143,032 $ - $ 2,527,596

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Oct. 31, 2022
Share Capital
SUMMARY OF WARRANTS ISSUED AND OUTSTANDING	Continuity of the warrants issued and outstanding as follows: SUMMARY OF WARRANTS ISSUED AND OUTSTANDING Number of warrants Weighted average exercise price Outstanding, January 31, 2020 - $ - Granted 730,258 7.87 Outstanding, January 31, 2021 and October 31, 2021 730,258 $ 7.87 Granted - - Outstanding, January 31, 2021 and October 31, 2021 730,258 $ 7.87 Granted 4,351,967 4.22 Outstanding, October 31, 2022 5,082,225 $ 4.75
SUMMARY OF WARRANTS OUTSTANDING	The following table discloses the number of warrants outstanding as at October 31, 2022: SUMMARY OF WARRANTS OUTSTANDING Number of warrants Price Expiry date 181,869 CAD$ 3.47 June 30, 2023 86,537 $ 2.85 June 30, 2023 461,852 CAD$ 10.42 June 30, 2023 4,089,126 $ 4.16 August 4, 2027 262,841 $ 5.20 August 4, 2027 5,082,225
SUMMARY OF RESTRICTED SHARE AWARDS	SUMMARY OF RESTRICTED SHARE AWARDS Number of RSUs Weighted average grant date fair value Outstanding, January 31, 2021 and October 31, 2021 - $ - Granted 492,228 2.85 Outstanding, October 31, 2022 492,228 $ 2.85 Vested, October 31, 2022 - $ -

DERIVATIVE WARRANT LIABILITY (T

DERIVATIVE WARRANT LIABILITY (Tables)	12 Months Ended
	Oct. 31, 2022
Derivative Warrant Liability
SCHEDULE OF DERIVATIVE WARRANT LIABILITY	The following is a continuity of the Company’s derivative warrant liability: SCHEDULE OF DERIVATIVE WARRANT LIABILITY Balance, January 31, 2020 $ - Issued during the period 953,850 Change in fair value of derivative 536,209 Balance, January 31, 2021 $ 1,490,059 Change in fair value of derivative 92,918 Balance, October 31, 2021 $ 1,582,977 Beginning balance $ 1,582,977 Issued during the period 5,535,852 Change in fair value of derivative (5,740,202 ) Derecognition of warrant derivative (136,047 ) Balance, October 31, 2022 $ 1,242,580 Ending b alance $ 1,242,580

FINANCIAL INSTRUMENT RISK MAN_2

FINANCIAL INSTRUMENT RISK MANAGEMENT (Tables)	12 Months Ended
	Oct. 31, 2022
Financial Instrument Risk Management
SCHEDULE OF FINANCIAL ASSETS	Financial assets included in the statement of financial position are as follows: SCHEDULE OF FINANCIAL ASSETS Level in fair October 31, 2022 October 31, 2021 January 31, 2021 Amortized cost: Cash $ 72,921 $ 14,530 $ 692,647 Term deposit 18,506 - - Accounts receivable 175,256 161,047 81,159 Financial assets $ 266,683 $ 175,577 $ 773,806
SCHEDULE OF FINANCIAL LIABILITIES	Financial liabilities included in the statement of financial position are as follows: SCHEDULE OF FINANCIAL LIABILITIES Level in fair October 31, 2022 October 31, 2021 January 31, 2021 Amortized cost: Accounts payable and accrued expenses $ 1,345,288 $ 3,366,062 $ 308,719 Loans payable - 27,144 17,580 FVTPL: Warrant derivative liability Level 3 1,242,580 1,582,977 1,490,059 Financial liabilities $ 2,587,868 $ 4,976,183 $ 1,816,358
SCHEDULE OF UNOBSERVABLE INPUTS LIABILITY	For the fair values of the derivative liability, reasonably possible changes to the expected volatility, the most significant unobservable input would have the following effects: SCHEDULE OF UNOBSERVABLE INPUTS LIABILITY Unobservable Inputs Change Impact on comprehensive loss 12 months ended October 31, 2022 9 months ended October 31, 2021 12 months ended January 31, 2021 Volatility 20 % $ 537,641 $ 258,303 $ 144,370
SCHEDULE OF ANALYSIS OF CONTRACTUAL MATURITIES FINANCIAL LIABILITIES	The following is an analysis of the contractual maturities of the Company’s financial liabilities as at October 31, 2022: SCHEDULE OF ANALYSIS OF CONTRACTUAL MATURITIES FINANCIAL LIABILITIES Within one year Between one More than five Accounts payable and accrued expenses $ 1,345,288 $ - $ -

SEGMENTED INFORMATION (Tables)

SEGMENTED INFORMATION (Tables)	12 Months Ended
	Oct. 31, 2022
Segmented Information
SCHEDULE OF SALES BY GEOGRAPHICAL REGION	The Company’s breakdown of sales by geographical region is as follows: SCHEDULE OF SALES BY GEOGRAPHICAL REGION 12-months ended 9-months ended 12-months ended United States of America $ 1,656,215 $ 1,238,259 $ 512,094 Canada 976,227 727,182 389,068 Revenue $ 2,632,442 $ 1,965,441 $ 901,162
SCHEDULE OF SALES BY PRODUCT SEGMENT	The Company’s breakdown of sales by product segment is as follows: SCHEDULE OF SALES BY PRODUCT SEGMENT 12-months ended 9-months ended 12-months ended Devices $ 1,663,939 $ 1,367,778 $ 817,778 Consumables 968,503 597,663 83,384 Revenue $ 2,632,442 $ 1,965,441 $ 901,162

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2022
Income Taxes
SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSES (RECOVERY)	SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSES (RECOVERY) 12-months ended 9-months ended 12-months ended Net loss $ (8,765,271 ) $ (4,211,271 ) $ (8,890,431 ) Statutory income tax rate 26.50 % 26.50 % 26.50 % Income tax benefit computed at the statutory tax rate (2,322,797 ) (1,115,987 ) (2,355,964 ) Non-deductible items (1,375,505 ) 62,336 1,457,569 Financing fees charged to equity (487,828 ) - (106,022 ) Change in tax assets not recognized 4,186,130 1,053,651 1,004,417 Income tax recovery $ - $ - $ -
SCHEDULE OF DEFERRED TAX ASSET AND LIABILITIES	The Company had the following unrecognized deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSET AND LIABILITIES October 31, 2022 October 31, 2021 January 31, 2021 Non-capital losses $ 6,357,780 $ 2,541,736 $ 1,467,401 Equipment 1,549 520 - Share issuance costs 432,671 63,613 84,818 Total 6,792,000 2,605,869 1,552,219 Unrecognized deferred tax assets (6,792,000 ) (2,605,869 ) (1,552,219 ) Net deferred tax assets $ - $ - $ -

SUMMARY OF ACCOUNTS AND OTHER R

SUMMARY OF ACCOUNTS AND OTHER RECEIVABLES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Accounts And Other Receivables
Trade receivables	$ 103,471	$ 36,734	$ 7,206
Sales taxes receivable	71,785	124,313	73,953
Total	$ 175,256	$ 161,047	$ 81,159

SUMMARY OF PREPAID EXPENSES AND

SUMMARY OF PREPAID EXPENSES AND DEPOSITS (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Prepaid Expenses And Deposits
Prepaid expenses	$ 191,322	$ 18,246	$ 7,067
Deposits on inventory	475,458	56,261	111,302
Deposits	10,694	7,067
Total	$ 677,474	$ 81,574	$ 118,369

SUMMARY OF ACCOUNTS PAYABLE AND

SUMMARY OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Accounts Payable And Accrued Liabilities
Accounts payable	$ 909,438	$ 2,299,177	$ 236,806
Accrued liabilities	435,850	1,066,885	71,913
Total	$ 1,345,288	$ 3,366,062	$ 308,719

SCHEDULE OF SENIOR SECURED PROM

SCHEDULE OF SENIOR SECURED PROMISSORY NOTES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022
IfrsStatementLineItems [Line Items]
Balance, January 31, 2021 and October 31, 2021
Additions		4,650,000
Discount		(150,000)
Transaction costs		(639,250)
Accretion		992,117
Repayment		(4,852,867)
Balance, October 31, 2022
December senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Balance, January 31, 2021 and October 31, 2021
Additions		3,000,000
Discount
Transaction costs		(396,500)
Accretion		527,382
Repayment		(3,130,882)
Balance, October 31, 2022
April senior secured promissory note [member]
IfrsStatementLineItems [Line Items]
Balance, January 31, 2021 and October 31, 2021
Additions		1,650,000
Discount		(150,000)
Transaction costs		(242,750)
Accretion		464,735
Repayment		(1,721,985)
Balance, October 31, 2022

SCHEDULE OF AMOUNTS DUE TO RELA

SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES (Details) - USD ($)		9 Months Ended	12 Months Ended
	Jun. 24, 2020	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
Director fees		$ 26,339	$ 91,050	$ 11,207
Professional fees		241,854	521,064	222,870
Consulting fees	$ 275,918
Related parties [member]
IfrsStatementLineItems [Line Items]
Director fees		72,541	107,168	54,585
Professional fees			327,370	55,625
Share-based compensation			128,729	1,997,611
Key management personnel of entity or parent [member]
IfrsStatementLineItems [Line Items]
Consulting fees		270,427		206,507
Salaries			686,615
Share-based compensation			$ 143,032	$ 2,527,596

SUMMARY OF WARRANTS ISSUED AND

SUMMARY OF WARRANTS ISSUED AND OUTSTANDING (Details)	9 Months Ended	12 Months Ended
	Oct. 31, 2021 shares $ / shares	Oct. 31, 2022 shares $ / shares	Jan. 31, 2021 shares $ / shares
Share Capital
Number of warrants beginning balance | shares	730,258	730,258
Weighted average exercise price, warrants beginning balance | $ / shares	$ 7.87	$ 7.87
Number of warrants, Granted | shares		4,351,967	730,258
Weighted average exercise price, Granted | $ / shares		$ 4.22	$ 7.87
Number of warrants ending balance | shares	730,258	5,082,225	730,258
Weighted average exercise price, warrants ending balance | $ / shares	$ 7.87	$ 4.75	$ 7.87

SUMMARY OF WARRANTS OUTSTANDING

SUMMARY OF WARRANTS OUTSTANDING (Details)	12 Months Ended
	Oct. 31, 2022 shares Segment $ / shares	Oct. 31, 2022 shares Segment $ / shares	Oct. 31, 2021 shares $ / shares	Jan. 31, 2021 shares $ / shares	Jan. 31, 2020 shares $ / shares
IfrsStatementLineItems [Line Items]
Number of warrants | shares	5,082,225	5,082,225	730,258	730,258
Exercise price of warrants | $ / shares	$ 4.75		$ 7.87	$ 7.87
Warrants one [member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	181,869	181,869
Exercise price of warrants | $ / shares		$ 3.47
Warrants expiry date	Jun. 30, 2023
Warrants two [member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	86,537	86,537
Exercise price of warrants | $ / shares	$ 2.85
Warrants expiry date	Jun. 30, 2023
Warrants three [member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	461,852	461,852
Exercise price of warrants | $ / shares		$ 10.42
Warrants expiry date	Jun. 30, 2023
Warrants four [member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	4,089,126	4,089,126
Exercise price of warrants | $ / shares	$ 4.16
Warrants expiry date	Aug. 04, 2027
Warrants five [member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	262,841	262,841
Exercise price of warrants | $ / shares	$ 5.20
Warrants expiry date	Aug. 04, 2027
Warrants Six [Member]
IfrsStatementLineItems [Line Items]
Number of warrants | Segment	5,082,225	5,082,225

SUMMARY OF RESTRICTED SHARE AWA

SUMMARY OF RESTRICTED SHARE AWARDS (Details)	9 Months Ended	12 Months Ended
	Oct. 31, 2021 shares $ / shares	Oct. 31, 2022 shares $ / shares	Jan. 31, 2021 shares $ / shares
IfrsStatementLineItems [Line Items]
Number of warrants beginning balance | shares	730,258	730,258
Weighted average exercise price, warrants beginning balance | $ / shares	$ 7.87	$ 7.87
Number of RSUs, Granted | shares		4,351,967	730,258
Weighted average exercise price, Granted | $ / shares		$ 4.22	$ 7.87
Number of warrants ending balance | shares	730,258	5,082,225	730,258
Weighted average exercise price, warrants ending balance | $ / shares	$ 7.87	$ 4.75	$ 7.87
Restricted share awards [member]
IfrsStatementLineItems [Line Items]
Number of warrants beginning balance | shares
Weighted average exercise price, warrants beginning balance | $ / shares
Number of RSUs, Granted | shares		492,228
Weighted average exercise price, Granted | $ / shares		$ 2.85
Number of warrants ending balance | shares		492,228
Weighted average exercise price, warrants ending balance | $ / shares		$ 2.85
Number of RSUs, Vested, ending balance | shares
Weighted average exercise price, Vested, ending balance | $ / shares

SCHEDULE OF DERIVATIVE WARRANT

SCHEDULE OF DERIVATIVE WARRANT LIABILITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Derivative Warrant Liability
Beginning balance	$ 1,490,059	$ 1,582,977
Issued during the period		5,535,852	953,850
Change in fair value of derivative	92,918	(5,740,202)	536,209
Derecognition of warrant derivative		(136,047)
Ending balance	$ 1,582,977	$ 1,242,580	$ 1,490,059

SCHEDULE OF FINANCIAL ASSETS (D

SCHEDULE OF FINANCIAL ASSETS (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021	Jan. 31, 2020
Financial Instrument Risk Management
Cash	$ 72,921	$ 14,530	$ 692,647	$ 180,651
Term deposit	18,506
Accounts receivable	175,256	161,047	81,159
Financial assets	$ 266,683	$ 175,577	$ 773,806

SCHEDULE OF FINANCIAL LIABILITI

SCHEDULE OF FINANCIAL LIABILITIES (Details) - USD ($)	Oct. 31, 2022	Aug. 05, 2022	Oct. 31, 2021	Jan. 31, 2021	Jan. 31, 2020
IfrsStatementLineItems [Line Items]
Accounts payable and accrued expenses	$ 1,345,288		$ 3,366,062	$ 308,719
Loans payable			27,144	17,580
Warrant derivative liability	1,242,580	$ 5,047,704	1,582,977	1,490,059
Financial liabilities	2,587,868		4,976,183	1,816,358
Level 2 of fair value hierarchy [member]
IfrsStatementLineItems [Line Items]
Warrant derivative liability	$ 1,242,580		$ 1,582,977	$ 1,490,059

SCHEDULE OF UNOBSERVABLE INPUTS

SCHEDULE OF UNOBSERVABLE INPUTS LIABILITY (Details) - Historical volatility for shares, measurement input [member]	Oct. 31, 2022 USD ($)	Oct. 31, 2021 USD ($)	Jan. 31, 2021 USD ($)
IfrsStatementLineItems [Line Items]
Volatility percentage	20
Volatility	537,641	258,303	144,370

SCHEDULE OF ANALYSIS OF CONTRAC

SCHEDULE OF ANALYSIS OF CONTRACTUAL MATURITIES FINANCIAL LIABILITIES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
Accounts payable and accrued expenses	$ 1,345,288	$ 3,366,062	$ 308,719
With one year [member]
IfrsStatementLineItems [Line Items]
Accounts payable and accrued expenses	1,345,288
Between one and five years [member]
IfrsStatementLineItems [Line Items]
Accounts payable and accrued expenses
More than five years [member]
IfrsStatementLineItems [Line Items]
Accounts payable and accrued expenses

SCHEDULE OF SALES BY GEOGRAPHIC

SCHEDULE OF SALES BY GEOGRAPHICAL REGION (Details) - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
Revenue	$ 1,965,441	$ 2,632,442	$ 901,162
United state of america [member]
IfrsStatementLineItems [Line Items]
Revenue	1,238,259	1,656,215	512,094
Canada [member]
IfrsStatementLineItems [Line Items]
Revenue	$ 727,182	$ 976,227	$ 389,068

SCHEDULE OF SALES BY PRODUCT SE

SCHEDULE OF SALES BY PRODUCT SEGMENT (Details) - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
IfrsStatementLineItems [Line Items]
Revenue	$ 1,965,441	$ 2,632,442	$ 901,162
Devices [member]
IfrsStatementLineItems [Line Items]
Revenue	1,367,778	1,663,939	817,778
Consumables [member]
IfrsStatementLineItems [Line Items]
Revenue	$ 597,663	$ 968,503	$ 83,384

SCHEDULE OF RECONCILIATION OF I

SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSES (RECOVERY) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Income Taxes
Net loss	$ (4,211,271)	$ (8,765,271)	$ (8,890,431)
Statutory income tax rate	26.50%	26.50%	26.50%
Income tax benefit computed at the statutory tax rate	$ (1,115,987)	$ (2,322,797)	$ (2,355,964)
Non-deductible items	62,336	(1,375,505)	1,457,569
Financing fees charged to equity		(487,828)	(106,022)
Change in tax assets not recognized	1,053,651	4,186,130	1,004,417
Income tax recovery

SCHEDULE OF DEFERRED TAX ASSET

SCHEDULE OF DEFERRED TAX ASSET AND LIABILITIES (Details) - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Income Taxes
Non-capital losses	$ 6,357,780	$ 2,541,736	$ 1,467,401
Equipment	1,549	520
Share issuance costs	432,671	63,613	84,818
Total	6,792,000	2,605,869	1,552,219
Unrecognized deferred tax assets	(6,792,000)	(2,605,869)	(1,552,219)
Net deferred tax assets